Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Monozygotic twins discordant for recessive dystrophic epidermolysis bullosa phenotype highlight the role of TGF-β signalling in modifying disease severity.
[dystrophic epidermolysis bullosa]
Recessive
dystrophic
epidermolysis
bullosa
(
RDEB
)
is
a
genodermatosis
characterized
by
fragile
skin
forming
blisters
that
heal
invariably
with
scars
.
It
is
due
to
mutations
in
the
COL
7
A
1
gene
encoding
type
VII
collagen
,
the
major
component
of
anchoring
fibrils
connecting
the
cutaneous
basement
membrane
to
the
dermis
.
Identical
COL
7
A
1
mutations
often
result
in
inter-
and
intra-familial
disease
variability
,
suggesting
that
additional
modifiers
contribute
to
RDEB
course
.
Here
,
we
studied
a
monozygotic
twin
pair
with
RDEB
presenting
markedly
different
phenotypic
manifestations
,
while
expressing
similar
amounts
of
collagen
VII
.
Genome-
wide
expression
analysis
in
twins
'
fibroblasts
showed
differential
expression
of
genes
associated
with
TGF-β
pathway
inhibition
.
In
particular
,
decorin
,
a
skin
matrix
component
with
anti-fibrotic
properties
,
was
found
to
be
more
expressed
in
the
less
affected
twin
.
Accordingly
,
fibroblasts
from
the
more
affected
sibling
manifested
a
profibrotic
and
contractile
phenotype
characterized
by
enhanced
α-smooth
muscle
actin
and
plasminogen
activator
inhibitor
1
expression
,
collagen
I
release
and
collagen
lattice
contraction
.
These
cells
also
produced
increased
amounts
of
proinflammatory
cytokines
interleukin
6
and
monocyte
chemoattractant
protein-
1
.
Both
TGF-β
canonical
(
Smads
)
and
non-canonical
(
MAPKs
)
pathways
were
basally
more
activated
in
the
fibroblasts
of
the
more
affected
twin
.
The
profibrotic
behaviour
of
these
fibroblasts
was
suppressed
by
decorin
delivery
to
cells
.
Our
data
show
that
the
amount
of
type
VII
collagen
is
not
the
only
determinant
of
RDEB
clinical
severity
,
and
indicate
an
involvement
of
TGF-β
pathways
in
modulating
disease
variability
.
Moreover
,
our
findings
identify
decorin
as
a
possible
anti-fibrotic
/
inflammatory
agent
for
RDEB
therapeutic
intervention
.
Diseases
Validation
Diseases presenting
"inter"
symptom
dystrophic epidermolysis bullosa
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom